Volasertib trihydrochloride

Description: Volasertib (BI 6727) trihydrochloride is a dihydropteridinone derivative that potently and selectively inhibits Polo-like kinase 1 (PLK1), PLK2, and PLK3, acting as an orally active ATP-competitive inhibitor with an IC50 of 0.87 nM against PLK1, 5 nM against PLK2, and 56 nM against PLK3. Its mechanism includes inducing mitotic arrest and apoptosis, with significant antitumor activity observed in various cancer models. Target: Others. Smiles: Cl.Cl.Cl.CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O , wU:28.29,5.1,wD:25.22,(16.69,,,,-12.23,,4.18,-12.23,,-12.27,2.97,,-10.94,3.74,,-9.6,2.97,,-8.27,3.74,,-8.27,5.28,,-9.6,6.05,,-6.94,6.05,,-6.94,2.97,,-5.6,3.74,,-4.27,2.97,,-2.93,3.74,,-1.6,2.97,,-1.6,1.43,,-.27,.66,,1.07,1.43,,1.07,2.97,,-.27,3.74,,-.27,5.28,,1.07,6.05,,2.4,.66,,3.73,1.43,,2.4,-.88,,3.73,-1.65,,3.73,-3.19,,5.07,-3.96,,6.4,-3.19,,6.4,-1.65,,5.07,-.88,,7.74,-3.96,,9.07,-3.19,,10.4,-3.96,,10.4,-5.5,,11.74,-6.27,,11.74,-7.81,,12.51,-9.15,,10.97,-9.15,,9.07,-6.27,,7.74,-5.5,,-4.27,1.43,,-5.6,.66,,-6.94,1.43,,-8.27,.66,,-8.27,-.88,,-9.6,1.43,,-10.94,.66,),